Long-Term Monitoring of the Antibody Response to a SARS-CoV-2 Infection.
COVID-19
SARS-CoV-2
antibody
immunoassay
nucleocapsid protein
serological diagnostics
time period
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
16 Oct 2021
16 Oct 2021
Historique:
received:
17
08
2021
revised:
13
10
2021
accepted:
13
10
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
A group of 110 patients from the West Bohemian region who had been infected with COVID-19 was monitored for the purposes of this study. We focused on cases of mild or moderate COVID-19; statistically the most likely to occur. Day zero was defined as the day on which a positive PCR test was first established. The mean length of observation was 6.5 months, the maximum length 12 months. The first blood samples were taken from a smaller cohort during the 1-3 months following the first positive PCR test. We assumed that SARS-CoV-2 antibodies would be present during this period and therefore a limited number of samples were taken for the purpose of detecting antibodies. More samples were collected, starting 4 months after the first positive PCR test. A subsequent set of blood samples were drawn, mostly 6 months after the first ones. Our study confirmed the presence of total IgG SARS-CoV-2 antibodies up to 1 year after the onset of the disease. The peak of antibody production was observed in the third month after the first positive PCR test. A mathematical estimate of the median duration of antibody positivity was calculated to be 18 months from the onset of the COVID-19 infection.
Identifiants
pubmed: 34679613
pii: diagnostics11101915
doi: 10.3390/diagnostics11101915
pmc: PMC8534661
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Surg. 2020 Jun;78:123-125
pubmed: 32360932
EBioMedicine. 2020 Sep;59:102915
pubmed: 32747185
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
J Geriatr Oncol. 2020 Sep;11(7):1187-1188
pubmed: 32467027
Cell Mol Immunol. 2020 Jul;17(7):773-775
pubmed: 32467617
J Gen Virol. 2020 Aug;101(8):791-797
pubmed: 32430094
J Intern Med. 2021 Apr;289(4):559-573
pubmed: 33034095
Emerg Microbes Infect. 2020 Dec;9(1):940-948
pubmed: 32357808
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
J Clin Virol. 2020 Oct;131:104611
pubmed: 32882666
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
PLoS One. 2020 Dec 31;15(12):e0244126
pubmed: 33382764
J Med Virol. 2020 Oct;92(10):2050-2054
pubmed: 32383183
Nat Commun. 2020 Nov 27;11(1):6044
pubmed: 33247152
Eur J Immunol. 2021 Mar;51(3):634-647
pubmed: 33251605
Front Microbiol. 2020 Oct 19;11:584251
pubmed: 33193227
J Infect. 2020 Jul;81(1):147-178
pubmed: 32209385
Viruses. 2021 Apr 30;13(5):
pubmed: 33946311
Diagnostics (Basel). 2021 Mar 25;11(4):
pubmed: 33806216
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033173
Vaccines (Basel). 2020 May 14;8(2):
pubmed: 32423059
Front Immunol. 2020 Dec 16;11:610300
pubmed: 33391280
PLoS One. 2021 Jun 3;16(6):e0252628
pubmed: 34081747